With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab) has been added to the Costco Member ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA ... solution in a single-dose, prefilled syringe.

Celltrion is introducing Steqeymaq (ustekinumab-stba), which is a biosimilar to Johnson & Johnson's Stelara (ustekinumab). Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic ...

Stelara (ustekinumab, Janssen) is an interleukin (IL)-12 and IL-23 inhibitor approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

"In addition to approving Otulfi last year for all indications matching the reference product Stelara, the FDA has ... a 45 mg/0.5 mL and 90 mg/mL single-dose prefilled syringe for injection ...

FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United ... a 45 mg/0.5 mL and 90 mg/mL single-dose prefilled syringe for injection and a 130 mg/26 mL (5 mg/mL ...

JERSEY CITY, N.J., March 12, 2025 /PRNewswire/ -- Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA&circledR ... 5 mL or 90mg/1 mL solution in ...

STEQEYMA ®, one of the first-wave biosimilars to STELARA ®, is now available in ... 45mg/0.5 mL or 90mg/1 mL solution in a single-dose, prefilled syringe. The intravenous infusion is provided ...

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, representing a 462% increase over prior yearAdjusted EBITDA in ...

STEQEYMA ®, one of the first-wave biosimilars to STELARA ®, is now available in the U.S. Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale ...